Efficacy and Safety of Risankizumab in Crohn's Disease: A Systematic Review and Meta-Analysis of Randomized Trials and Real-World Evidence.

Dig Dis SciMay 18, 2026 (epub)
Clinical ResearchGastroenterologyOpen access

Alaa Abdrabou Abouelmagd, Mazen Negmeldin Yassin, Dina Essam Abo-Elnour et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the efficacy and safety of Risankizumab (RZB) in patients with moderate-to-severe Crohn's disease, incorporating data from five randomized controlled trials and nine observational studies (n=3275). RZB significantly improved clinical remission rates at induction (RR: 1.90) and maintenance (RR: 1.34) compared to placebo, with favorable safety outcomes.

Key findings

  • RZB increased clinical remission rates at induction (RR: 1.90) and maintenance (RR: 1.34) compared to placebo.
  • Endoscopic remission was significantly higher with RZB at induction (RR: 3.25) and maintenance (RR: 2.04).
  • Pooled real-world evidence showed clinical remission rates of 57% at 12 weeks and 44% at 1 year.

Why it matters

The findings highlight Risankizumab's effectiveness in achieving and maintaining remission in Crohn's disease, particularly in patients who have failed previous biologic therapies. This information is crucial for clinicians managing complex cases.

Source

PubMed · PMID 42151576Free full text on PubMed Central

Published in Dig Dis Sci. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.